NAD+observational1989

Photolabeling of Glu-129 of the S-1 subunit of pertussis toxin with NAD.

Infection and immunity

confidence

Key findings

UV irradiation transferred nicotinamide from NAD to Glu-129 of S-1 subunit; replacement with glycine/aspartic acid blocked labeling, implicating Glu-129 as active-site residue.

View source on PubMed (PMID 2807535) ↗

Population
In vitro recombinant protein (C180 peptide) containing catalytic region of S-1 subunit of pertussis toxin
Dosing
[3H-nicotinamide]NAD and [32P-adenylate]NAD
Route
in vitro photolabeling
Blinding
not_reported
Controls
none
Drug class
coenzyme
Full abstract

UV irradiation was shown to induce efficient transfer of radiolabel from nicotinamide-labeled NAD to a recombinant protein (C180 peptide) containing the catalytic region of the S-1 subunit of pertussis toxin. Incorporation of label from [3H-nicotinamide]NAD was efficient (0.5 to 0.6 mol/mol of protein) relative to incorporation from [32P-adenylate]NAD (0.2 mol/mol of protein). Label from [3H-nicotinamide]NAD was specifically associated with Glu-129. Replacement of Glu-129 with glycine or aspartic acid made the protein refractory to photolabeling with [3H-nicotinamide]NAD, whereas replacement of a nearby glutamic acid, Glu-139, with serine did not. Photolabeling of the C180 peptide with NAD is similar to that observed with diphtheria toxin and exotoxin A of Pseudomonas aeruginosa, in which the nicotinamide portion of NAD is transferred to Glu-148 and Glu-553, respectively, in the two toxins. These results implicate Glu-129 of the S-1 subunit as an active-site residue and a potentially important site for genetic modification of pertussis toxin for development of an acellular vaccine against Bordetella pertussis.

Research information, not medical advice. StudyKit summarizes published studies to help you understand your protocol. It does not diagnose, treat, or replace a clinician. Talk to a qualified provider before changing anything you take.